Q4 2023 Earnings Forecast for United Therapeutics Co. Issued By Zacks Research (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Analysts at Zacks Research lowered their Q4 2023 earnings per share (EPS) estimates for shares of United Therapeutics in a note issued to investors on Tuesday, September 5th. Zacks Research analyst K. Shah now anticipates that the biotechnology company will earn $3.62 per share for the quarter, down from their previous estimate of $3.66. The consensus estimate for United Therapeutics’ current full-year earnings is $18.95 per share. Zacks Research also issued estimates for United Therapeutics’ Q1 2024 earnings at $3.92 EPS, Q2 2024 earnings at $4.57 EPS, Q3 2024 earnings at $4.55 EPS, Q4 2024 earnings at $4.26 EPS, FY2024 earnings at $17.30 EPS, Q1 2025 earnings at $4.45 EPS and Q2 2025 earnings at $4.92 EPS.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $5.24 EPS for the quarter, beating the consensus estimate of $4.57 by $0.67. United Therapeutics had a return on equity of 17.52% and a net margin of 41.29%. The firm had revenue of $596.50 million during the quarter, compared to the consensus estimate of $524.18 million. During the same period in the prior year, the company earned $2.41 EPS. The firm’s revenue was up 27.8% compared to the same quarter last year.

Several other brokerages have also recently issued reports on UTHR. LADENBURG THALM/SH SH upped their price objective on shares of United Therapeutics from $256.00 to $268.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. Wedbush upped their price objective on shares of United Therapeutics from $305.00 to $307.00 and gave the company an “outperform” rating in a report on Thursday, August 3rd. StockNews.com initiated coverage on shares of United Therapeutics in a research report on Thursday, August 17th. They set a “buy” rating for the company. Morgan Stanley boosted their target price on shares of United Therapeutics from $316.00 to $318.00 and gave the company an “overweight” rating in a report on Thursday, August 3rd. Finally, HC Wainwright restated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $296.44.

United Therapeutics Stock Down 0.8 %

Shares of NASDAQ UTHR opened at $223.36 on Wednesday. United Therapeutics has a 12-month low of $201.65 and a 12-month high of $283.09. The stock has a market cap of $10.48 billion, a PE ratio of 12.58 and a beta of 0.62. The company has a current ratio of 8.68, a quick ratio of 8.40 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average of $231.77 and a 200 day moving average of $227.27.

Insider Activity

In other news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, July 6th. The shares were sold at an average price of $215.19, for a total value of $1,291,140.00. Following the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at approximately $7,875,738.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Paul A. Mahon sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $243.87, for a total value of $609,675.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares of the company’s stock, valued at $8,925,398.13. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 6th. The shares were sold at an average price of $215.19, for a total transaction of $1,291,140.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at approximately $7,875,738.81. The disclosure for this sale can be found here. In the last three months, insiders have sold 20,500 shares of company stock valued at $4,684,935. Company insiders own 12.50% of the company’s stock.

Institutional Trading of United Therapeutics

Several hedge funds have recently modified their holdings of UTHR. Massmutual Trust Co. FSB ADV grew its stake in shares of United Therapeutics by 61.4% during the second quarter. Massmutual Trust Co. FSB ADV now owns 163 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 62 shares in the last quarter. Machina Capital S.A.S. purchased a new stake in United Therapeutics during the first quarter worth approximately $45,000. Neo Ivy Capital Management purchased a new stake in United Therapeutics during the second quarter worth approximately $48,000. Global Retirement Partners LLC lifted its stake in United Therapeutics by 198.7% during the first quarter. Global Retirement Partners LLC now owns 224 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 149 shares during the last quarter. Finally, Atlas Capital Advisors LLC purchased a new stake in United Therapeutics during the fourth quarter worth approximately $51,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.